As previously informed, at the end of 2019, IDL Biotech signed a cooperation agreement with the Chinese company Zecen Biotech, regarding automation of the tumor marker TPS® on all Zecen Biotech’s instruments. The development project has proceeded very well and the first phase has been completed. Thus, the last phase before launch now begins. The hope is that the product will be available on the Chinese market by the end of 2021.
Read the full press release here (swedish)
During 2015 the patent Method for detection of cytokeratin 8, 18 and/or 19 and/or soluble fragments thereof was approved in Sweden. In September 2017 the patent was approved in China. The patent has now also been approved in Europe and is valid until 2034.
Results from a Czech Republic study. Breast cancer represents 24 % of all cancer occurring in women. Breast cancer is the most common malignancy and the second most frequent cause of death by cancer in women. Although the incidence rate of breast cancer has been...
IDL Biotech tumor marker MonoTotal® ELISA has been registered by the Swedish Medical Product Agency for the use in the EU. MonoTotal® is used for diagnosis, prognosis and therapy monitoring of lung cancer. MonoTotal® has previously only been...
